Univariate and multivariable Cox models for prediction of new-onset AF by sex-specific SUA quartiles and systolic BP as time-varying covariates
| Variable | Number of subsequent events | Univariate | Multivariable | Wald | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| SUA 2nd Quartile | 373 | 0.59 (0.43–0.80) | 0.001 | 0.87 (0.58–1.30) | 0.499 | 0.46 |
| SUA 3rd Quartile | 373 | 0.83 (0.65–1.07) | 0.158 | 1.14 (0.79–1.64) | 0.499 | 0.46 |
| SUA 4th Quartile | 373 | 1.84 (1.50–2.25) | < 0.001 | 1.65 (1.19–2.29) | 0.003 | 8.88 |
| Systolic BP, per SD | 373 | 0.95 (0.87–1.04) | 0.273 | 0.92 (0.84–1.00) | 0.044 | 4.06 |
| Cornell voltage-duration product, per SD | 373 | 1.15 (1.05–1.25) | 0.003 | 1.10 (1.01–1.21) | 0.033 | 4.56 |
| Framingham risk score, per SD | 373 | 1.25 (1.14–1.38) | < 0.001 | 0.94 (0.82–1.08) | 0.401 | 0.71 |
| Cerebrovascular disease | 373 | 1.50 (1.20–1.86) | < 0.001 | 1.20 (0.96–1.50) | 0.114 | 2.50 |
| Age, per SD | 373 | 1.89 (1.69–2.12) | < 0.001 | 1.94 (1.72–2.20) | < 0.001 | 115.0 |
| Male gender | 373 | 1.27 (1.03–1.55) | 0.022 | 1.44 (1.08–1.92) | 0.014 | 6.01 |
| Atenolol treatment | 373 | 1.40 (1.14–1.72) | 0.001 | 1.35 (1.10–1.66) | 0.005 | 7.97 |
1st through 4th SUA quartiles at baseline using sex-specific ranges: < 309, 309–353, 354–408, and ≥ 409 μmol/L for men and < 255, 255–297, 298–345, and ≥ 346 μmol/L for women. 1st quartile n = 2,033, 2nd quartile n = 2,070, 3rd quartile n = 2,100, 4th quartile n = 2,040. SD: standard deviation